The EANM guideline for radiosynoviorthesis
© 2021. The Author(s)..
PURPOSE: Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.
METHODS: The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.
CONCLUSION: These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine and molecular imaging - 49(2022), 2 vom: 17. Jan., Seite 681-708 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kampen, W U [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arthritis |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00259-021-05541-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332120317 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332120317 | ||
| 003 | DE-627 | ||
| 005 | 20231225214939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-021-05541-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332120317 | ||
| 035 | |a (NLM)34671820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kampen, W U |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The EANM guideline for radiosynoviorthesis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a PURPOSE: Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain | ||
| 520 | |a METHODS: The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed | ||
| 520 | |a CONCLUSION: These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arthritis | |
| 650 | 4 | |a Radiosynoviorthesis | |
| 650 | 4 | |a Synovitis | |
| 650 | 7 | |a Radiopharmaceuticals |2 NLM | |
| 700 | 1 | |a Boddenberg-Pätzold, B |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gabriel, M |e verfasserin |4 aut | |
| 700 | 1 | |a Klett, R |e verfasserin |4 aut | |
| 700 | 1 | |a Konijnenberg, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kresnik, E |e verfasserin |4 aut | |
| 700 | 1 | |a Lellouche, H |e verfasserin |4 aut | |
| 700 | 1 | |a Paycha, F |e verfasserin |4 aut | |
| 700 | 1 | |a Terslev, L |e verfasserin |4 aut | |
| 700 | 1 | |a Turkmen, C |e verfasserin |4 aut | |
| 700 | 1 | |a van der Zant, F |e verfasserin |4 aut | |
| 700 | 1 | |a Antunovic, L |e verfasserin |4 aut | |
| 700 | 1 | |a Panagiotidis, E |e verfasserin |4 aut | |
| 700 | 1 | |a Gnanasegaran, G |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwert, T |e verfasserin |4 aut | |
| 700 | 1 | |a Van den Wyngaert, T |e verfasserin |4 aut | |
| 700 | 0 | |a EANM Bone & Joint Committee, the Dosimetry Committee, the Oncology & Theranostics Committee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d 2002 |g 49(2022), 2 vom: 17. Jan., Seite 681-708 |w (DE-627)NLM116957360 |x 1619-7089 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:2 |g day:17 |g month:01 |g pages:681-708 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-021-05541-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 2 |b 17 |c 01 |h 681-708 | ||